The general public may not yet need COVID-19 booster doses, according to a new review; a significant incidence of anxiety tied to climate change and government inaction is being reported in young people; COVID-19 infections in US children have increased by approximately 240% since early July.
According to an expert review of scientific evidence on COVID-19 vaccine efficacy published in The Lancet, booster doses were indicated to not be needed for the general public at this time. Reported by CNBC, findings from researchers, which included scientists of the FDA and World Health Organization, show that COVID-19 vaccines in the United States continue to provide highly effective protection against severe disease and hospitalization caused by the Delta variant. Acknowledging that booster shots may be needed at a later date, the researchers said there are risks associated with distributing booster doses too soon, such as potential incidence of myocarditis, which is more common after the second dose of mRNA vaccines.
As reported by ABC News, a study published today in Lancet Planetary Health found a significant incidence of anxiety in young people related to climate change and government handling of such crises. Surveying 10,000 people aged 16 to 25, 45% of respondents said their feelings of climate change negatively affect their daily life and functioning, with 75% also reporting fear of the future. Notably, 58% of young people said governments are betraying them and 61% said governments are not protecting them, the planet, or future generations.
A recent American Academy of Pediatrics study shows that COVID-19 infections in US children has markedly increased, by about 240%, since early July, when kids accounted for 71,726 cases. Reported by CNN, nearly 500,000 new cases of COVID-19 have been reported among children in the last 2 weeks, which comes as students under the age of 12, who are not eligible for vaccination, are beginning in-person classes nationwide. Currently, children account for 29% of all cases reported across the country.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Camlipixant May Benefit Patients With High-Burden RCC
June 25th 2025A phase 2a trial of camlipixant, a selective P2X3 receptor antagonist, found that while the drug did not significantly reduce cough frequency in the overall population with refractory chronic cough, it produced meaningful improvements in patients with a higher baseline cough burden.
Read More